supported by the National Natural Science Foundation of China(No.81172037);Science and Technology Program of Guangdong Province,China(No.2013B021800159);Clinical Trials Project(308 Project)of Sun Yat-sen University Cancer Center(No.308-2015-014).
Background:The optimal strategy for adjuvant therapy after curative resection for hepatocellular carcinoma(HCC)patients with solitary tumor and microvascular invasion(MVI)is controversial.This trial evaluated the effi...